BloodFlow
AI platform integrating into hospital EHRs for real-time blood test interpretations.
Website: https://www.bloodflow.eu
Cover Block
| Attribute | Value |
|---|---|
| Company Name | BloodFlow |
| Tagline | AI platform integrating into hospital EHRs for real-time blood test interpretations. |
| Headquarters | Lisbon, Portugal |
| Founded | 2024 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed Funding | €1.2M [Portugal Startup News, July 2025] |
Links
- Website. https://websummit.com/appearances/lis25/4b90f19b-94d6-4b6a-826b-8e7ae176a170/bloodflow/ [Web Summit, 2025]
- LinkedIn. https://www.linkedin.com/company/bloodflow2024 [LinkedIn, 2025]
- GitHub. https://github.com/tiagodccosta [GitHub, 2026]
The Short Version
BloodFlow is a Lisbon-based healthtech startup that has secured seed funding to deploy an AI platform for real-time clinical interpretation of blood tests directly within hospital electronic health record (EHR) systems [Portugal Startup News, July 2025]. The company's focus is on a high-volume, routine diagnostic workflow and an on-premise deployment model, addressing data privacy concerns in European healthcare [Perplexity Sonar Pro Brief, 2025].
Founded in October 2024 by solo founder Tiago Costa, the company's origins are in a self-built prototype developed while Costa finished his computer engineering degree [The Next Big Idea, 2025]. The core product is an API that integrates via the HL7 FHIR standard, aiming to transform raw lab results into explainable insights for clinicians without data leaving hospital infrastructure [Perplexity Sonar Pro Brief, 2025].
Costa's background combines software engineering with a history as a former high-performance athlete for Sporting CP [ECO, July 2025]. The business model is B2B, targeting hospital systems as primary customers, with future ambitions including pharmaceutical trials [Portugal Startup News, July 2025].
In July 2025, the company closed a €1.2 million seed round led by the Lisbon-based private equity firm 3xP Global. Capital is earmarked for team expansion and pursuing medical device certifications [3xP Global, July 2025]. Over the next 12-18 months, key milestones include initial hospital pilot deployments, regulatory pathways, and scaling the technical and commercial teams.
Data Accuracy: YELLOW -- Core funding and product claims are reported by multiple Portuguese outlets, but customer traction and technical validation are not publicly available.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed |
The Company in Brief
BloodFlow is a Lisbon-based healthtech startup founded in October 2024. Tiago Costa, a computer engineering graduate, built the first version of the platform alone while finishing his degree and working full-time [The Next Big Idea, 2025]. Costa is also a former high-performance athlete with Sporting CP [ECO, July 2025].
The company's first major external milestone was a €1.2 million seed financing round announced in July 2025, led by the Health Innovation Fund of 3xP Global [Portugal Startup News, July 2025]. The capital is intended for team expansion, market entry, and pursuing necessary regulatory certifications for medical devices [3xP Global, July 2025].
Data Accuracy: YELLOW -- Key founding details and funding amount sourced from Portuguese business press and investor announcement; founder background corroborated across multiple local outlets.
What They Have Built
BloodFlow's core proposition is an AI platform designed to integrate directly into hospital electronic health record (EHR) systems to automate the interpretation of routine blood test results. The platform is a plug-and-play API that connects via the HL7 FHIR interoperability standard and is engineered to run fully on-premise to keep patient data within hospital infrastructure [Perplexity Sonar Pro Brief, 2025]. The intended output is real-time, explainable insights delivered to clinicians [Portugal Startup News, July 2025].
The company's GitHub profile lists a project titled 'Automating Blood Tests Analysis with Artificial Intelligence,' though it does not specify the models, training data, or validation methodology [GitHub, 2026].
- Primary surface. The product is marketed as an API-first solution for hospitals, with a wedge into blood diagnostics.
- Deployment model. A fully on-premise architecture is a stated requirement [Perplexity Sonar Pro Brief, 2025].
- Expansion intent. Public announcements indicate plans to expand the platform's use cases to support pharmaceutical clinical trials and pursue medical device certification [Portugal Startup News, July 2025].
Data Accuracy: YELLOW -- Product claims are sourced from press releases and a brief; technical implementation details are not independently verified.
Market Research and Opportunity
The broader AI in medical diagnostics market was valued at approximately $1.5 billion in 2023 and is projected to grow at a compound annual rate of around 30% through 2030 [Grand View Research, 2023]. Demand drivers include a persistent shortage of clinical specialists, the administrative burden of interpreting high volumes of routine tests, and a growing emphasis on value-based care [Portugal Startup News, July 2025].
| Metric | Value |
|---|---|
| AI in Medical Diagnostics (2023) | 1.5 $B |
| Projected CAGR (2023-2030) | 30 % |
Data Accuracy: YELLOW -- Market sizing is based on an analogous, broader sector report. Demand drivers and regulatory context are cited from company and investor announcements.
Who Else Is Fighting for This
BloodFlow enters a healthtech segment defined by a crowded field of AI-driven diagnostic aids. In the segment for AI-powered blood test analysis, competition includes specialized diagnostic AI startups like Kantesti, BloodGPT, and Hathr.ai, as well as large, horizontal clinical decision support and EHR vendors. BloodFlow aims to displace traditional laboratory information systems (LIS) and manual interpretation workflows [Perplexity Sonar Pro Brief, 2025].
BloodFlow's claimed edge rests on its plug-and-play API for HL7 FHIR standards and its fully on-premise deployment model [Perplexity Sonar Pro Brief, 2025]. The company lacks a disclosed commercial footprint and faces execution risks related to its solo founder structure and the need for domain expertise in regulatory affairs or clinical sales.
Data Accuracy: YELLOW -- BloodFlow's claimed differentiators are from a single secondary source.
Opportunity
The company's initial technical wedge targets a high-volume, repetitive clinical task using an HL7 FHIR standard integration [Perplexity Sonar Pro Brief, 2025]. The €1.2 million seed funding is earmarked for pursuing medical device certification [Portugal Startup News, July 2025] [3xP Global, July 2025].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regulatory-Cleared Platform | BloodFlow obtains CE Mark or similar certification as a Class II medical device for its AI, enabling direct sales to public health systems and use in formal diagnostic pathways. | Successful completion of a retrospective clinical validation study, a stated use of seed funding [Portugal Startup News, July 2025]. | The product is designed for a regulated environment (on-premise, explainable AI), and the funding is explicitly tied to this goal. |
| Pharma Trials Partnership | The platform is adopted by pharmaceutical companies as a tool for patient screening and biomarker monitoring in clinical trials, creating a high-ACV, project-based revenue stream. | A partnership announcement with a mid-sized European CRO or pharma company to pilot the technology. | The company has publicly stated expansion into pharma clinical trials as a target market [Perplexity Sonar Pro Brief, 2025]. |
Data Accuracy: YELLOW -- Core opportunity thesis is built on company-stated goals and technical approach from a single briefing; market comparables are from public sources.
Sources
[Portugal Startup News, July 2025] BloodFlow secures €1.2M seed funding to transform blood test analysis | https://portugalstartupnews.com/2025/07/25/bloodflow-secures-e1-2m-seed-funding-to-transform-blood-test-analysis/
[3xP Global, July 2025] 3xP Global Invests in BloodFlow to Advance Real-Time Diagnostic Insights | https://www.3xpglobal.eu/news/3xp-global-invests-in-bloodflow
[The Next Big Idea, 2025] BloodFlow fecha ronda seed de 1,2 milhões para levar IA às análises de sangue | https://thenextbigidea.pt/bloodflow-fecha-ronda-seed-de-12-milhoes-para-levar-ia-as-analises-de-sangue/
[ECO, July 2025] Ex-atleta do Sporting levanta 1,2 milhões para ‘acelerar’ análises ao sangue com inteligência artificial | https://eco.sapo.pt/2025/07/30/ex-atleta-do-sporting-levanta-1,2-milhoes-para-acelerar-analises-ao-sangue-com-inteligencia-artificial/
[Dealroom, 2025] BloodFlow | https://app.dealroom.co/companies/bloodflow
[LinkedIn, 2025] BloodFlow | https://www.linkedin.com/company/bloodflow2024
[Web Summit, 2025] BloodFlow | Web Summit | https://websummit.com/appearances/lis25/4b90f19b-94d6-4b6a-826b-8e7ae176a170/bloodflow/
[GitHub, 2026] tiagodccosta (Tiago Costa) · GitHub | https://github.com/tiagodccosta
[Perplexity Sonar Pro Brief, 2025] BloodFlow Briefing
[Grand View Research, 2023] AI in Medical Diagnostics Market Report
Articles about BloodFlow
- BloodFlow Is Wiring AI Into Hospital Blood Tests — The Lisbon startup's on-premise platform aims to interpret routine lab results in real time, a €1.2M seed bet on a crowded clinical AI field.